Trials / Unknown
UnknownNCT03669562
The Safety and Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers
The Safety, Tolerability and Pharmacokinetic Phrase I Study of Alprostadil Fat Emulsiom Injection in Healthy Adult Volunteers
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
Conducted in Chinese healthy adult volunteers,the study aims to observe the safety, tolerability and pharmacokinetic of single-dose administration of different doses of Alprostadil Liposome for Injection as well as to confirm the safety dose range.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alprostadil Liposome for Injection | intravenous infusion Alprostadil Liposome |
| DRUG | Placebo | intravenous infusion liposome control |
Timeline
- Start date
- 2018-08-07
- Primary completion
- 2018-10-15
- Completion
- 2018-10-30
- First posted
- 2018-09-13
- Last updated
- 2018-09-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03669562. Inclusion in this directory is not an endorsement.